Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Getz gets Port-Access in Japan:

This article was originally published in Clinica

Executive Summary

Getz is to have exclusive distribution rights to Heartport's Port-Access minimally-invasive cardiac surgery systems in Japan. California-based Getz will obtain regulatory approvals and reimbursement for the systems as well as training Japanese surgical teams. Heartport's product allows surgeons to perform heart operations through a small incision between the ribs. Some 900,000 people in Japan have ischemic heart disease and more than 30,000 people undergo open heart surgery annually. Getz claims to be the largest healthcare export marketing and services company in the US with offices in 23 countries.

You may also be interested in...



Viatris’ UpJohn Breaking Taboo Around Erectile Dysfunction With UK PR Campaign

Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals. 

Top 100 Outlook 2021: Medtechs Look To Build On Experiences Of Serving Global Markets In A Pandemic

Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.

Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19

2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

Topics

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel